Phase 2 study of nilotinib as third‐line therapy for patients with gastrointestinal stromal tumor

Patients with gastrointestinal stromal tumors (GISTs) resistant to both imatinib and sunitinib have a poor prognosis and few therapeutic options. In this study, the efficacy and safety of nilotinib (AMN107) as a third‐line therapy for patients with GISTs was evaluated.

[1]  Heikki Joensuu,et al.  Practical management of tyrosine kinase inhibitor-associated side effects in GIST. , 2011, Cancer treatment reviews.

[2]  Nikolaus Stiefl,et al.  Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. , 2010, Bioorganic & medicinal chemistry.

[3]  J. Blay,et al.  Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. , 2010 .

[4]  M. Heinrich,et al.  Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.

[5]  J. Blay,et al.  A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.

[6]  H. Joensuu,et al.  Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. , 2009, European journal of cancer.

[7]  T. Naoe,et al.  A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL , 2009, International journal of hematology.

[8]  C. Antonescu,et al.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Patrick Schöffski,et al.  Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure , 2008 .

[10]  Narasimhan P. Agaram,et al.  Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors , 2008, Clinical Cancer Research.

[11]  J. Radich,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. , 2008, Blood.

[12]  Narasimhan P. Agaram,et al.  Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor , 2007, Clinical Cancer Research.

[13]  J. Blay,et al.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Narasimhan P. Agaram,et al.  Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors , 2007, Clinical Cancer Research.

[15]  J. Desai,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[16]  P. Manley,et al.  OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. , 2006, Blood.

[17]  M. Debiec‐Rychter,et al.  Cellular Uptake of the Tyrosine Kinase Inhibitors Imatinib and AMN107 in Gastrointestinal Stromal Tumor Cell Lines , 2006, Pharmacology.

[18]  M. Pirmohamed,et al.  hOCT 1 and resistance to imatinib. , 2005, Blood.

[19]  J. Blay,et al.  Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. , 2005, European journal of cancer.

[20]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[21]  Munir Pirmohamed,et al.  Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.

[22]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[23]  Wei Zhang,et al.  A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors , 2004, Cancer Research.

[24]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[26]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[27]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[28]  J. Michael.  Textbook of Medical Physiology , 2005 .